OncoHost
2 known investors
OncoHost develops a blood-based diagnostic test that uses proteomic pattern recognition and AI to predict patient benefit from PD-1/PD-L1 immunotherapy inhibitors for oncology treatment planning. The platform analyzes tumor and host microenvironment factors in plasma or serum samples to generate personalized treatment recommendations.